In this video from the virtual Euretina congress, Quan Dong Nguyen, MD, MSc, speaks about ABY-035, a novel biologic compound that has been demonstrated to be a potent interleukin-17A inhibitor with unique pharmacological properties.
ABY-035 (Affibody) is currently under investigation in the LINNAEA international, multicenter, phase 2 study evaluating efficacy and safety in the treatment and prevention of relapse/recurrence of noninfectious intermediate, posterior or panuveitis.